Jason Kelly, Ginkgo Bioworks CEO (Adam Glanzman/Bloomberg via Getty Images)
February 26, 2025 07:20 AM EST
Pharma
Manufacturing

Gink­go un­cer­tain over the fu­ture of US gov­ern­ment fund­ing, stock drops

Anna Brown

News Reporter

Gink­go Bioworks’ stock $DNA fell by around 13% pre­mar­ket Wednes­day af­ter the com­pa­ny damp­ened its 2025 sales fore­cast.

“We are be­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Leo Phar­ma says its years­long makeover is about to pay off

Mer­ck says Keytru­da could be up next for IRA price cuts

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times